Fintel reports that on October 13, 2025, HC Wainwright & Co. reiterated coverage of MannKind (NasdaqGM:MNKD) with a Buy ...
MannKind remains a Buy, driven by Tyvaso DPI's strong market position and Technosphere platform optionality. Learn more about ...
In a report released today, Faisal Khurshid from Leerink Partners resumed coverage with a Buy rating on MannKind and a price target of $9.00. The company’s shares opened today at $5.20. Take advantage ...
TipRanks on MSN
MannKind Completes Acquisition of scPharma
MannKind ( ($MNKD) ) just unveiled an announcement. On October 7, 2025, MannKind completed the acquisition of scPharma, making it a wholly-owned ...
Walleye Capital LLC lessened its holdings in shares of MannKind Corporation (NASDAQ:MNKD – Free Report) by 28.4% in the 1st quarter, according to the company in its most recent Form 13F filing with ...
MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback